Cancer Clinical Trial
Official title:
Assessment of Anabolic Responsiveness to Protein Intake in Advanced Cancer
Verified date | March 2018 |
Source | Texas A&M University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Weight loss and muscle wasting commonly occurs in patients with cancer, negatively
influencing their quality of life, treatment response and survival. Weight changes in
patients with cancer may be the consequence of energy imbalance and disturbances in protein
metabolism, poor treatment tolerance, hormonal alterations, systemic inflammation etc. This
results in body composition modifications in favor of fat gain and/or lean body mass loss in
early stage cancer. However, in advanced cancer mostly loss of both fat mass and lean mass
has been found.
Unfortunately, gains in muscle mass are difficult to achieve. In a previous study of the
Investigators, a bolus (15 g) of an essential amino acid mixture as present in milk protein
was able to stimulate whole-body protein anabolism equally and effectively in weight-losing
patients with lung cancer. This indicates the high potential of proteins with high essential
amino acids as therapeutic agents to increase muscle mass in these patients. However, the
dose-response effect to reach optimal whole-body protein anabolism is yet unknown and can
differ among patients. Therefore, the Investigators would like to study the effects of
several dosages of a protein with high essential amino acid levels, administered by sip
feeding, on whole-body protein anabolism in patients with cancer in comparison with healthy
older adults. Furthermore, the individual protein requirements of cancer patients may be
established as this is the cornerstone of nutritional support. Specifically to establish 'the
anabolic threshold', when protein breakdown equals synthesis and the response and the
relation between protein intake and net protein synthesis are critical.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 2019 |
Est. primary completion date | May 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria cancer subjects: - Age 18 years or older - Ability to lie in supine or elevated position for 8 hours - Diagnosed with stage III/IV cancer (all solid tumors excluding breast or prostate) - No chemotherapy/radiotherapy within past month prior to the study day - Willingness and ability to comply with the protocol Inclusion criteria healthy subjects: - Healthy male or female according to the investigator's or appointed staff's judgment - Age 18 years or older - Ability to lay in supine or elevated position for 8 hours - No diagnosis of cancer - No diagnosis of diabetes - Willingness and ability to comply with the protocol Exclusion Criteria all subjects: - Any condition that may interfere with the definition 'healthy subject' according to the investigator's judgment (for healthy control group only) - Presence of fever within the last 3 days - Untreated metabolic diseases including hepatic or renal disorder - Presence of acute illness or metabolically unstable chronic illness - BMI of < 18.5 or = 35 kg/m2 (for healthy control group only) - Dietary or lifestyle characteristics: Current alcohol or drug abuse, Use of protein or amino acid containing nutritional supplements within 5 days prior to the study day - Known allergy to milk or milk products - Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements - (Possible) pregnancy - Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient |
Country | Name | City | State |
---|---|---|---|
United States | Texas A&M University-CTRAL | College Station | Texas |
Lead Sponsor | Collaborator |
---|---|
Texas A&M University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in net whole-body protein synthesis | Change in whole-body protein synthesis rate after intake of meal | 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180, 210, 225, 240, 260, 280, 300, 320, 340, 360 ± 5 min | |
Secondary | Body Composition | Body composition as measured by Dual-Energy X-ray Absorptiometry | 15 minutes on screening or study day 1 | |
Secondary | Skeletal muscle strength | handgrip | on study day 1 | |
Secondary | Skeletal muscle strength | kin-com 1-leg test | on study day 1 | |
Secondary | Respiratory muscle strength | Maximum inhalation and exhalation pressure | on study day 1 | |
Secondary | Gut function | Digestion of the stable tracers of amino acid | In postabsorptive and prandial state every 20 minutes up to 6 hours before each sip feeding on study day | |
Secondary | Group differences in state of mood as measured by the Hospital Anxiety and Depression Scale (HADS) | a fourteen item self-assessment scale. Seven of the items related to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | Group differences in activity as measured by Physical Activity Scale for the Elderly (PASE) | questionnaire is intended for use in an elderly population and focuses on 3 types of activities: leisure time activities, household activities and work-related activities. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | Group differences in state of mood as measured by the Profile of Mood State (POMS) | A psychological distress scale to measure mood disturbance in 6 domains - fatigue-inertia, vigor-activity, tension-anxiety, depression-dejection, anger-hostility, and confusion-bewilderment. Healthy populations take 3 to 7 minutes to complete, and others may take up a bit longer. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | appetite questionnaire | The subject is asked to rate various aspects of their appetite as relates to overall health | study day 1 | |
Secondary | Group differences in attention and executive functions as measured by Stroop Color-Word Test (SCWT) | a word page with words printed in black ink, a color page with blocks printed in color, and a color-word page where the color and the word do not match. The examinee reads the words or names the ink colors as quickly as possible within a time limit. Measures selective attention and inhibitory control. The total time in seconds was reported for each trial. | Postabsorptive state during 3 hours and change after feeding on study day 1] | |
Secondary | Group differences in learning and memory as measured by Controlled Oral Word Association Test (COWAT) | The examinee is required to say as many words as they can think of in one minute that begin with a given letter of the alphabet. The task contains three trials. Measures phonetic verbal fluency. The raw score (total and mean words recorded across the three trials) was reported. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | Group differences in overall cognitive abilities as measured by Montreal Cognitive Assessment (MoCA) | assesses several cognitive domains and is used for the screening of mild cognitive impairment. Total scores range from 0-30 with lower scores indicating decreased functioning. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | Group differences in attention and executive functions as measured by Brief-A | a standardized self-report that captures views of an adult's executive functions or self-regulation in his or her everyday environment. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | diet recall | The subject is asked to recall in detail all the food and drink consumed during the 24 hours prior to the test day. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | Group differences in attention and executive functions as measured by Trail Making Test (TMT) | Part A, the examinee is instructed to connect a set of 25 circles with numbers as quickly as possible while maintaining accuracy. In Part B, the examinee is instructed to connect a set of 25 circles, alternating between numbers and letters, as quickly as possible while maintaining accuracy. Measures attentional resources and is a measure of the frontal lobe "executive" functions of visual search, set-switching and mental flexibility. The total time in seconds was reported for each measure. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | Functional Status | Functional status will be assessed by the Karnofsky Performance Score, a widely used method to assess the functional status of a cancer patient. It describes a patient's functional status as a comprehensive 11-point scale ranging from 0% to 100%. | Postabsorptive state during 3 hours and change after feeding on study day 1 | |
Secondary | Group differences in learning and memory as measured by Auditory Verbal Learning Test (AVLT) | a verbal episodic memory test that evaluates a wide diversity of functions: short-term auditory-verbal memory, rate of learning, retention and recognition of information. | Postabsorptive state during 3 hours and change after feeding on study day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|